Dr. Andrew Salzman is a Harvard-trained physician, biomedical researcher, inventor, and entrepreneur whose work stretches far beyond today’s longevity supplement conversation. Long before NMN became popular, Salzman was researching PARP enzymes, inflammation, oxidative damage, intestinal injury, and experimental drug development.

More recently, he has become known for his views on NAD+, NMN, cellular repair, and aging. He also serves as Chief Medical Officer at Wonderfeel, where he has helped develop NMN-based products. (1)

Understanding both sides of his career matters. His earlier scientific work is substantial, while some newer claims around NMN and aging still sit in an area where human evidence is developing.

Key Takeaways:

• Dr. Andrew Salzman trained at Harvard Medical School and has published more than 170 research papers, according to his Wonderfeel profile. (1)

• Much of his earlier work involved PARP, inflammation, oxidative stress, and cellular injury.

• He later became a prominent advocate for supporting NAD+ levels through NMN.

• Human NMN trials show promising changes in NAD+ and a few health markers, but there is no human evidence that NMN extends lifespan.

Who Is Dr. Andrew Salzman?

Andrew Salzman, MD, is a physician, researcher, inventor, and biotechnology entrepreneur.

According to his current Wonderfeel biography, he studied at Yale University, Harvard Medical School, and Columbia University. The company credits him with more than 170 published research papers, over 60 patents, and more than $165 million in NIH research funding. (1)

Today, he is closely associated with longevity science. But much of his research career predates the current interest in NMN.

That distinction is worth making.

Salzman spent years studying cellular injury, inflammation, DNA repair pathways, and experimental medicines. That work later connected naturally with NAD+, since several enzymes involved in cellular repair consume NAD+ as part of their activity.

What Is Dr. Salzman Known for in Medical Research?

One of Salzman’s main research areas has been poly(ADP-ribose) polymerase, better known as PARP.

PARP enzymes help cells respond to DNA damage. When DNA becomes damaged, PARP uses NAD+ while coordinating parts of the repair process.

There is a catch. Excessive PARP activity can consume large amounts of cellular NAD+ and ATP, potentially contributing to energy failure and cell injury.

Salzman researched this pathway in areas including inflammation, cardiovascular injury, intestinal damage, and critical illness.

His work also moved beyond laboratory models.

Salzman was a co-author of the TIMI 37 clinical trial, which tested the PARP inhibitor INO-1001 in 40 people undergoing treatment for ST-elevation myocardial infarction. 

The drug reduced measured PARP activity by more than 90% across the tested doses and was considered well tolerated in the study. 

The trial was designed mainly to examine safety, pharmacokinetics, and biological activity, not to show that the treatment reduced heart attacks or deaths. (2)

That clinical background is an important part of Salzman’s story and gets little attention in most profiles about his longevity work.

How Does Salzman Connect NAD+ With Aging?

NAD+, or nicotinamide adenine dinucleotide, is a molecule that cells need for energy metabolism and many signaling processes.

It also serves as a substrate for enzymes including PARPs, sirtuins, and CD38.

Salzman has spoken extensively about a possible tug-of-war that develops with age. DNA damage and inflammation may increase activity of NAD+-consuming enzymes, while the body’s ability to maintain NAD+ can also change.

From that perspective, keeping more NAD+ available could support cellular energy production and repair.

Parts of this biology are well established. The bigger question is what raising NAD+ through supplements translates to in humans.

A higher NAD+ measurement does not automatically mean slower aging, better health, or longer life. That is where NMN research becomes important.

What Does Dr. Salzman Say About NMN?

Salzman has become a strong supporter of nicotinamide mononucleotide, or NMN, a molecule the body can use to make NAD+.

He is also involved commercially. Salzman serves as Chief Medical Officer at Wonderfeel and has helped develop the company’s NMN formulation. (1)

Commercial involvement does not cancel out his scientific background, but it is useful context when evaluating claims.

Fortunately, NMN has now reached several human clinical trials.

One of the better-known studies involved 25 postmenopausal women with prediabetes who were overweight or obese. Participants taking 250 mg of NMN daily for 10 weeks experienced a 25 ± 7% increase in skeletal muscle insulin sensitivity. 

NMN also increased NAD+ in peripheral blood mononuclear cells. However, NAD+ levels inside skeletal muscle itself did not significantly rise. (3)

That last detail matters. NMN may affect NAD metabolism differently across tissues.

Another randomized trial tested 300 mg, 600 mg, or 900 mg of NMN daily for 60 days in 80 healthy adults aged 40 to 65. Blood NAD concentrations increased in the NMN groups, and researchers also reported changes in six-minute walking distance and some self-reported health measures. (4)

Those findings are interesting, but short trials cannot tell us if NMN slows biological aging over many years.

What Does the Bigger Picture Say About NMN?

Individual studies can look impressive. Looking across several trials gives a more grounded picture.

A 2024 systematic review and meta-analysis examined 12 randomized trials involving 513 adults. NMN significantly increased blood NAD levels. 

However, the researchers found little evidence of meaningful changes in fasting glucose, triglycerides, total cholesterol, LDL cholesterol, or HDL cholesterol. (5)

So the evidence currently looks stronger for this statement:

NMN can increase blood NAD-related measurements in humans.

It is much weaker for statements such as:

NMN reverses aging, prevents age-related disease, or extends human lifespan.

No human trial has demonstrated those outcomes.

That does not mean NMN has no value. It means researchers still have a lot to learn about what higher NAD+ levels translate to over months, years, and decades.

One NMN Question Is Still Being Debated

There is even disagreement about how NMN enters cells.

A 2019 paper proposed that a protein called SLC12A8 acts as a specific NMN transporter, allowing NMN to enter cells directly. (6)

Later that year, other researchers challenged the finding. They argued that the experimental evidence did not establish SLC12A8 as a specific NMN transporter and pointed to evidence that extracellular NMN can first convert into nicotinamide riboside before entering cells. (7)

The original researchers responded and defended their findings. (8)

Why does this matter?

Supplement discussions can sometimes turn complicated biology into neat marketing lines. Biology rarely behaves that neatly. Even something as basic as exactly how supplemental NMN reaches different cells remains under investigation.

Is Dr. Salzman’s NAD Research Credible?

Salzman has a genuine biomedical research background.

His work on PARP, DNA damage, inflammation, cellular energy failure, and drug development goes back decades. He also participated in human clinical research before becoming closely associated with NMN supplements.

That gives his views on NAD biology more scientific context than those of many public longevity commentators.

Still, credentials and evidence answer different questions.

A researcher can have an impressive career while some newer hypotheses remain unproven. With NMN, human studies support its ability to influence NAD metabolism, while its effects on long-term health and lifespan remain uncertain.

That distinction is more useful than placing Salzman entirely in either the “longevity pioneer” or “supplement promoter” box.

Final Words

Dr. Andrew Salzman’s interest in NAD did not appear out of nowhere. His earlier work on PARP and cellular injury provides a clear scientific bridge to his later focus on NAD+, NMN, and healthy aging.

Human research has now shown that NMN can raise blood NAD markers, and a few studies have found changes in insulin sensitivity or physical performance. Still, we do not yet have long-term human trials showing that NMN slows aging or extends lifespan.

For people interested in supporting NAD+ metabolism, NMN remains one of the more researched NAD precursors. 

At Omre, our NMN + Resveratrol formula combines NMN with trans-resveratrol in a research-led formula designed around healthy aging and cellular health, while keeping the claims in line with what human evidence can support today.

FAQs

Who is Dr. Andrew Salzman?

Dr. Andrew Salzman is a physician, biomedical researcher, inventor, and biotechnology entrepreneur. He trained at Harvard Medical School and has researched areas including PARP, inflammation, cellular injury, drug development, NAD+, and NMN.

What is Dr. Andrew Salzman known for?

His scientific work includes research into PARP enzymes, oxidative stress, inflammation, intestinal injury, and experimental drugs. More recently, he has become known for discussing NAD+, NMN, and healthy aging.

Does Dr. Salzman take NMN?

Salzman publicly supports NMN and is Chief Medical Officer at Wonderfeel, which sells an NMN supplement. Public information about his exact personal supplement routine may change, so it is better not to assume a specific daily dose.

Does research show that NMN raises NAD+?

Yes. Several short-term human trials have reported increases in blood NAD or related NAD metabolites after NMN supplementation. (3)(4)(5) Evidence for broader health outcomes is less consistent.

Has NMN been proven to slow aging?

No. Human studies have measured NAD levels, metabolic markers, physical performance, and other short-term outcomes, but no clinical trial has shown that NMN extends human lifespan or reverses aging.

References

1. Wonderfeel. Andrew Salzman, MD, Chief Medical Officer

2. Morrow DA, et al. TIMI 37 trial of the PARP inhibitor INO-1001

3. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

4. Yi L, et al. Efficacy and safety of NMN supplementation in healthy middle-aged adults

5. Huang H, et al. Systematic review and meta-analysis of NMN and glucose and lipid metabolism

6. Grozio A, et al. SLC12A8 is a nicotinamide mononucleotide transporter

7. Schmidt MS, Brenner C. Absence of evidence that SLC12A8 encodes an NMN transporter

8. Grozio A, et al. Reply regarding the proposed SLC12A8 NMN transporter